<DOC>
	<DOCNO>NCT02435030</DOCNO>
	<brief_summary>This prospective non-therapeutic observational study NP-C patient . The aim characterize individual patient disease progression profile historical 6 month prospective evaluation clinical , image , biological ( biomarkers ) quality life data . Patients offer enrollment Phase II/III study arimoclomol end study .</brief_summary>
	<brief_title>A Prospective Non-therapeutic Study Patients Diagnosed With Niemann-Pick Disease Type C</brief_title>
	<detailed_description />
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<criteria>Written inform consent ( assent appropriate local law regulation ) prior studyrelated procedure ; Males females age 2 year 18 year 11 month ; Patients ethnic background eligible study ; Patient weight ≥15th percentile body mass index ( BMI ) age accord World Health Organisation ( WHO ) standard ; Diagnosis Niemann Pick disease Type C ( NPC ) , either NPC1 NPC2 ; NPC diagnosis genetically confirm ( deoxyribonucleic acid [ DNA ] sequence analysis ) ; Both NPC1 NPC2 patient eligible ; Presenting least one neurological symptom disease ( example , limit , hear loss , vertical supranuclear gaze palsy , ataxia , dementia , dystonia , seizure , dysarthria , dysphagia ) ; Ability walk either independently assistance ; Ability travel correspond clinical trial site repeatedly ( every 6 month ) evaluation followup ; Treated nontreated miglustat ; If patient prescribed treatment miglustat , stable dose medication ≥ 3 continuous month prior inclusion study ; Sexually active patient must willing able use adequate method contraception throughout study , example : diaphragm + spermicide ; intrauterine contraceptive device ; oral contraceptive ; implant ; injection progestogen medication ; Ability comply protocolspecified procedures/evaluations schedule visit ; Willing participate aspect trial design include serial blood sampling , skin biopsy image ( ultrasonography ) collection . No write informed consent obtain patient parent ( ) /legal guardian ( ) ( assent appropriate local law regulation ) study related procedure ; Recipient liver transplant plan liver transplantation ; Patients uncontrolled severe epileptic seizure period ( least 3 consecutive severe epileptic seizure require medication ) within 2 month prior write consent . This include patient ongoing seizure stable frequency type duration 2 month period prior enrollment , require change dose antiepileptic medication ( adjustment weight ) 2 month period prior enrollment , require 3 antiepileptic medication control seizures ; Neurologically asymptomatic patient ; Severe liver insufficiency ( define hepatic laboratory parameter , aspartate transaminase [ AST ] alanine transaminase [ ALT ] great threetimes upper limit normal age gender ; Severe renal insufficiency , serum creatinine level great 1.5 time upper limit normal ; Severe manifestation NPC disease would interfere patient 's ability comply requirement protocol ; In opinion Investigator , patient 's clinical condition allow require blood collection and/or skin biopsy per protocolspecified procedure ; Treatment IMP within 4 week prior study enrollment ; Treatment IMP study attempt treat NPC ; Current participation another trial permit unless noninterventional study sole purpose trial longterm follow up/survival data ( registry ) ; Patients exclude confirm risk link MRI procedure perform subsequent therapeutic interventional study [ i.e . : implanted cardiac pacemaker implantable cardioverter defibrillator , implanted neural pacemaker , cochlear implant , implant metallic foreign body eye CNS ( CNS aneurysmal clip ) , form implanted wire metal device may concentrate radio frequency field and/or confirm history unexpected serious adverse reaction sedation anesthesia ( sedation necessary ) ] ; Patients exclude confirm risk link skin punch biopsy procedure like severe thrombocytopaenia , investigator 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>NP-C</keyword>
	<keyword>LSD</keyword>
	<keyword>lysosomal storage disorder</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>NPC2</keyword>
	<keyword>NPC1</keyword>
	<keyword>Niemann-Pick Type C</keyword>
	<keyword>Niemann-Pick ,</keyword>
	<keyword>Arimoclomol</keyword>
</DOC>